Patents and Postapproval Batch Testing - Can postapproval FDA filings immunize pharma companies from patent lawsuits? - BioPharm International

ADVERTISEMENT

Patents and Postapproval Batch Testing
Can postapproval FDA filings immunize pharma companies from patent lawsuits?


BioPharm International
Volume 25, Issue 12, pp. 55-56

REFERENCES

1. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 669-71 (1990).

2. 35 U.S.C. 271(e)(1) (2012).

3. 659 F.3d 1057, 1060, 1070 (Fed. Cir. 2011).

4. Ibid. at 1060.

5. Ibid. at 1070-72.

6. Ibid. at 1070.

7. 686 F.3d 1348 (Fed. Cir. 2012).

8. Ibid. at 1351.

9. Ibid. at 1353.

10. Ibid. at 1352-53.

11. Ibid. at 1354-55.

12. Ibid. at 1361-76.

13. Ibid. at 1357-58.

14. Petition for a Writ of Certiorari at i., GlaxoSmithKline v. Classen Immunotherapies, Inc., No. 11-1078 (U.S. Feb. 28, 2012).

15. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 206-07 (2005); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm International,
Click here